Open an account

Lexicon Pharmaceuticals

LXRX · NASDAQ

$1.58+$0.03 (+1.94%)TodayMarket closed ·
Prev close $1.55

About LXRX

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 81 full-time employees. The company went IPO on 2000-04-07. The firm is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The firm develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The firm also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.

Employees
81
Headquarters
The Woodlands, Texas
Listed
Apr 7, 2000
Sector
Health Care
Industry
Pharmaceuticals
Website
lexpharma.com

LXRX key statistics

Market cap
703.03M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.51M
Volume
1.41M
Open price
$1.56
High today
$1.63
Low today
$1.55
52 Week high
$2.68
52 Week low
$1.10

Lexicon Pharmaceuticals (LXRX) at a glance

As of Oct 20, 2026, Lexicon Pharmaceuticals (LXRX) shares are priced at $1.58, giving the company a market cap of 703.03M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.55 and $1.63. The current price is 2.3% above the day's low and 3.1% below its high.

Volume so far is 1.41M shares, below the average of 2.51M shares a day.

Over the past year Lexicon Pharmaceuticals has ranged from $1.10 to $2.68, and now sits 30% of the way up that range.

Lexicon Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.07 per share against an estimate of -$0.0512.

The average analyst price target is $4.64, 193.5% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $4.64
Low
$2.02
Now
$1.58
High
$8.40

LXRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 59.5% on average.

  1. Q3 FY24: reported -$0.18 per share against an estimate of -$0.1678
  2. Q4 FY24: reported -$0.09 per share against an estimate of -$0.1299
  3. Q1 FY25: reported -$0.07 per share against an estimate of -$0.0995
  4. Q2 FY25: reported $0.01 per share against an estimate of -$0.0791
  5. Q3 FY25: reported -$0.04 per share against an estimate of -$0.0673
  6. Q4 FY25: reported -$0.04 per share against an estimate of -$0.0704
  7. Q1 FY26: reported $0.00 per share against an estimate of -$0.0351
  8. Q2 FY26: reported -$0.07 per share against an estimate of -$0.0512

LXRX news

  • Avi Kapoor

    Beta Bionics, J.B. Hunt Transport And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Exploring Lexicon Pharmaceuticals's Earnings Expectations

  • Press releasePRNewswire

    Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

  • Avi Kapoor

    Gold Tumbles Over 6%; Apple Posts Upbeat Earnings

  • Press releasePRNewswire

    Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

  • Avi Kapoor

    Tilray Brands, SuperX AI Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session

  • Earnings Scheduled For November 6, 2025

Similar companies

Companies in the same industry as Lexicon Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.